future of glp-1 drugs What to Make the Coverage and Cost Landscape Could GLP-1 Drugs Reduce Obesity-Related

Acknowledgements We thank Milena Braga-Basaria, MD (Voxmed Medical Communications) for critically reviewing and suggesting improvements to the manuscript

As of April 30, 2025, there had been 520 reports involving compounded semaglutide and 480 for compounded tirzepatide

Diabetologia (1979) 16:7585

Consumers should review current information about any product's regulatory standing before purchasing

That risk differential increased to 14 percent a year after they stopped a GLP-1, and rose to as much as 22 percent after two years off the medication

Systematic studies that would address these interindividual differences in treatment response are expected to facilitate individualized treatment